Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Telemedicine could be something that is still used, even after the COVID-19 pandemic is over.
It has proven difficult to find new frontline treatments for schizophrenia, often due to the potential side effects of existing treatment.
For example, while effective, olanzapine can lead to substantial weight gain in patients, preventing the medication from having a broader reach.
However, a potential new treatment in ALKS 3831 could 1 day become that frontline treatment, especially for younger schizophrenia patients.
ALKS 3831 is a combination therapy of samidorphan and olanzapine and has been tested to target weight gain profiles of users in recent clinical trials.
The success of the trials has Alkermes officials, developers of the promising drug, hopeful it may eventually have an impact treating this patient population.
The once-daily treatment has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of Nov. 15, 2020 by the US Food and Drug Administration (FDA).
In an interview with HCPLive®, Adam Simmons, MPH, Director of Clinical Program Management, Alkermes, explained the impact the treatment could have it is ultimately approved by the FDA.
Simmons also discussed how some of the telemedicine practices implemented during the coronavirus disease 2019 (COVID-19) pandemic could continue to be utilized in clinical research even after the pandemic is over.